Étiquette : antipsychotique

CBD & the Psychedelic Receptor, Lex Pelger, projectCBD.org, 2019

CBD & the Psychedelic Receptor Lex Pelger On March 11, 2018 (Updated on April 16, 2019) https://www.projectcbd.org/science/cbd-psychedelic-receptor CBD and LSD bind to the same serotonin receptor, which mediates psychedelic altered states. But cannabidiol has anti-psychotic properties and doesn't cause hallucinations. In a shorthand that drives scientists mad, serotonin is often called ‘the neurotransmitter of happiness.’ This tag is especially troublesome as more and more flaws become apparent in the ‘serotonin hypothesis’ of depression – the idea that depression is caused by a serotonin deficit, which a pill (a serotonin reuptake inhibitor) could correct.1  Serotonin is a complex molecule in the brain and the [...]

Lire la suite

The Role of Cannabis within an Emerging Perspective on Schizophrenia, Jegason P. Diviant et al., 2018

The Role of Cannabis within an Emerging Perspective on Schizophrenia Jegason P. Diviant, Jacob M. Vigil, and Sarah S. Stith Medicines, 2018, 5, 86, 1-11. doi : 10.3390/medicines5030086   Abstract Background : Approximately 0.5% of the population is diagnosed with some form of schizophrenia, under the prevailing view that the pathology is best treated using pharmaceutical medications that act on monoamine receptors. Methods : We briefly review evidence on the impact of environmental forces, particularly the effect of autoimmune activity, in the expression of schizophrenic profiles and the role of Cannabis therapy for regulating immunological functioning. Results : A review of the literature shows that phytocannabinoid consumption may [...]

Lire la suite

Gene-environment interaction between an endocannabinoid system genetic polymorphism and cannabis use in first episode of psychosis, Miquel Bioque et al., 2019

Gene-environment interaction between an endocannabinoid system genetic polymorphism and cannabis use in first episode of psychosis Miquel Bioque, Sergi Mas, Maria Cristina Costanzo, Bibiana Cabrera, Antonio Lobo, Ana González-Pinto, Elisa Rodriguez-Toscano, Iluminada Corripio, Eduard Vieta, Immaculada Baeza, Ángela Ibáñez, Miguel Gutiérrez Fraile, Manuel J. Cuesta, Gisela Mezquida, Amalia Lafuente, Miguel Bernardo, PEPs GROUP European Neuropsychopharmacology, 2019, 29, (6), 786-794 https://doi.org/10.1016/j.euroneuro.2019.04.005   Abstract Alterations of the endocannabinoid system (ECS) may play an important role in the development of schizophrenia and other psychotic disorders. Cannabis use is one of the environmental fac- tors more repeatedly related to an increase the risk of developing a psychotic episode, while its [...]

Lire la suite

Could cannabidiol be used as an alternative to antipsychotics ?, Marc Fakhoury, 2016

Could cannabidiol be used as an alternative to antipsychotics ? Marc Fakhoury Journal of Psychiatric Research · May 2016 Doi : 10.1016/j.jpsychires.2016.05.013   Abstract Schizophrenia is a mental disorder that affects close to 1% of the population. Individuals with this disorder often present signs such as hallucination, anxiety, reduced attention, and social withdrawal. Although antipsychotic drugs remain the cornerstone of schizophrenia treatment, they are associated with severe side effects. Recently, the endocannabinoid system (ECS) has emerged as a potential therapeutic target for pharmacotherapy that is involved in a wide range of disorders, including schizophrenia. Since its discovery, a lot of effort has been devoted to the [...]

Lire la suite

In Vivo Availability of Cannabinoid 1 Receptor Levels in Patients With First-Episode Psychosis, Faith Borgan et al., 2019

In Vivo Availability of Cannabinoid 1 Receptor Levels in Patients With First-Episode Psychosis Faith Borgan, Heikki Laurikainen, Mattia Veronese, Tiago Reis Marques, Merja Haaparanta-Solin, Olof Solin, Tarik Dahoun, Maria Rogdaki, Raimo KR Salokangas, Max Karukivi, Marta Di Forti, Federico Turkheimer, Jarmo Hietala, Oliver Howes for the METSY Group JAMA Psychiatry, 2019. doi : 10.1001/jamapsychiatry.2019.1427   IMPORTANCE Experimental and epidemiological studies implicate the cannabinoid 1 receptor (CB1R) in the pathophysiology of psychosis. However, whether CB1R levels are altered in the early stages of psychosis and whether they are linked to cognitive function or symptom severity remain unknown. OBJECTIVE To investigate CB1R availability in first-episode psychosis (FEP) without the [...]

Lire la suite

Cannabidiol as a potential treatment for psychosis, Cathy Davies and Sagnik Bhattacharyya, 2019

Cannabidiol as a potential treatment for psychosis Cathy Davies and Sagnik Bhattacharyya Therapeutic Advances in Psychopharmacology, 2019, Vol. 9, 1–16 https://doi.org/10.1177%2F2045125319881916   Abstract : Psychotic disorders such as schizophrenia are heterogeneous and often debilitating conditions that contribute substantially to the global burden of disease. The introduction of dopamine D2 receptor antagonists in the 1950s revolutionised the treatment of psychotic disorders and they remain the mainstay of our treatment arsenal for psychosis. However, traditional antipsychotics are associated with a number of side effects and a significant proportion of patients do not achieve an adequate remission of symptoms. There is therefore a need for novel interventions, particularly those with a non-D2 antagonist mechanism of [...]

Lire la suite

Cannabidiol as a potential treatment for psychosis, C.D. Schubart et al., 2014

Cannabidiol as a potential treatment for psychosis C.D. Schubart, I.E.C. Sommer, P. Fusar-Poli, L. de Witte, R.S. Kahn, M.P.M. Boks European Neuropsychopharmacology, 2014, 24 ,(1), 51–64. http://dx.doi.org/10.1016/j.euroneuro.2013.11.002   Abstract Although cannabis use is associated with an increased risk of developing psychosis, the cannabis constituent cannabidiol (CBD) may have antipsychotic properties. This review concisely describes the role of the endocannabinoid system in the development of psychosis and provides an overview of currently available animal, human experimental, imaging, epidemiological and clinical studies that investigated the antipsychotic properties of CBD. In this targeted literature review we performed a search for English articles using Medline and EMBASE. Studies were selected if [...]

Lire la suite

Effects of cannabidiol (CBD) in neuropsychiatric disorders: A review of pre-clinical and clinical findings, Sonja ELSAID, 2019

Effects of cannabidiol (CBD) in neuropsychiatric disorders: A review of pre-clinical and clinical findings. Molecular Basis of Neuropsychiatric Disorders : from Bench to Bedside Sonja ELSAID, Stefan KLOIBER, Bernard Le FOLL Progress in Molecular Biology and Translational Science, 2019, 167, 25-75. doi : 10.1016/bs.pmbts.2019.06.005. Cannabis sativa (cannabis) is on of the oldest plants cultivated by men. Cannabidiol (CBD) is the major non-psychomimetic compound derived from cannabis. It has been proposed to have a therapeutic potential over a wide range of neuropsychiatric disorders. In this narrative review, we have summarized a selected number of pre-clinical and clinical studies, examining the effects of CBD in neuropsychiatric [...]

Lire la suite

Role of the Endocannabinoid System in the Pathophysiology of Schizophrenia, M. Fakhoury, 2017

Role of the Endocannabinoid System in the Pathophysiology of Schizophrenia M. Fakhoury Molecular Neurobiology, 2017, 54, (1), 768-778. doi: 10.1007/s12035-016-9697-5   ABSTRACT : The endocannabinoid system (ECS) is a group of neuromodulatory lipids, enzymes, and receptors involved in numerous behavioral and physiological processes such as mood, memory, and appetite. Recently, longitudinal and postmortem studies have shown that the ECS might be involved in neuropsychiatric disorders like schizophrenia. However, despite the large amount of research, our knowledge of the ECS and its implication in this debilitating disorder is still largely limited. This review aims at providing a comprehensive overview of the current state of knowledge of the [...]

Lire la suite

Therapeutic potential of cannabinoids in schizophrenia, KUCEROVA J. et al., 2014

Therapeutic potential of cannabinoids in schizophrenia, KUCEROVA J., TABIOVA K., DRAGO F., MICALE V. Recent Patents on CNS Drug Discovery, 2014, 9, (1), 13-25. Doi : 10.2174/1574889809666140307115532   Abstract Increasing evidence suggests a close relationship between the endocannabinoid system and schizophrenia. The endocannabinoid system comprises of two G protein-coupled receptors (the cannabinoid receptors 1 and 2 [CB1 and CB2] for marijuana's psychoactive principle Δ(9)-tetrahydro-cannabinol), their endogenous small lipid ligands (namely anandamide [AEA] and 2-arachidonoyl-glycerol [2-AG], also known as endocannabinoids), and proteins for endocannabinoid biosynthesis and degradation. It has been suggested to be a pro-homeostatic and pleiotropic signalling system activated in a time- and tissue-specific manner during [...]

Lire la suite